Florieke Eggermont, Ph.D.
I graduated from the Radboud University in 2013 (master’s degree Biomedical Sciences, major in Clinical Human Movement Sciences). I did my Master’s thesis within the Meniscus project at the ORL. In 2014 I started working as a scientific researcher on the Bone Metastases project. I obtained my PhD on 18 December 2019. I am now working as scientific researcher at the ORL on implementation of the BOS score, and as scientific lecturer for the studies Biomedical Sciences and Medicine at the Radboud University Nijmegen.
As a lecturer for the bachelors Biomedical Sciences and Medicine, I teach, but also help in the management of the minor ‘Moving questions: an introduction to Clinical Human Movement Sciences’, the Q6 module ‘Belasting en belastbaarheid’. In the master Biomedical Sciences, I am deputy specialisation coordinator Clinical Human Movement Sciences. Also, I coordinate the master course ‘Applied Matlab for Biomedical Problems’ and co-coordinate the master course ‘Orthopaedic Biomechanics in motion’. Additionally, I am a member of the Programme Committee Biomedical Sciences (opleidingscommissie BMW). Furthermore, I am a board member of the Vereniging voor Bewegingswetenschappen Nederland (VvBN, Dutch Society for Movement Sciences) and an editor for their magazine Moving Matters.
Bone metastases in patients with advanced cancer are very common and cause an increased risk of pathological fracture. Treatment is based on this fracture risk: patients with a low fracture risk are conservatively treated with local radiotherapy to relieve pain, whereas patients with a high fracture risk are considered for stabilizing prophylactic surgery. However, in present clinical practice, it appears to be difficult to differentiate between low and high fracture risk patients, causing a large number of over- and undertreated patients. Therefore, we want to improve the prediction of femoral fracture risk in patients with bone metastases with the use of patient-specific computer models, i.e. non-linear finite element (FE) models.
Our FE models have shown to be promising in an experimental setting (Thesis of Loes Derikx). In my PhD thesis, the computer simulations were validated in patients with cancer and bone metastases. Additionally, the computer simulations were further developed for large-scale clinical implementation. We are currently working on clinical implementation of the FE model, which we now call the BOneStrength score (or BOS score), see website and animation.